[go: up one dir, main page]

WO2008008558A1 - Système de test d'allergie peu invasif pourvu d'enrobages d'allergènes - Google Patents

Système de test d'allergie peu invasif pourvu d'enrobages d'allergènes Download PDF

Info

Publication number
WO2008008558A1
WO2008008558A1 PCT/US2007/061604 US2007061604W WO2008008558A1 WO 2008008558 A1 WO2008008558 A1 WO 2008008558A1 US 2007061604 W US2007061604 W US 2007061604W WO 2008008558 A1 WO2008008558 A1 WO 2008008558A1
Authority
WO
WIPO (PCT)
Prior art keywords
testing system
microneedle array
allergy testing
coated
allergen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/061604
Other languages
English (en)
Inventor
Jose Mir
Dennis Roland Zander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infotonics Technology Center Inc
Original Assignee
Infotonics Technology Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/026774 external-priority patent/WO2007008824A2/fr
Application filed by Infotonics Technology Center Inc filed Critical Infotonics Technology Center Inc
Priority to US12/373,385 priority Critical patent/US20100100005A1/en
Publication of WO2008008558A1 publication Critical patent/WO2008008558A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/685—Microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Definitions

  • the claimed invention generally relates to systems and methods for testing medical conditions and, more particularly, to systems used to determine a degree of reaction to one or more allergens by a subject in a minimally invasive manner.
  • Physicians prescribe allergy testing because early diagnosis can help patients take preventive measures such as managing their environment, avoiding certain drugs or foods, availing themselves of medication, immunotherapy, or self- administered epinephrine. Allergy tests such as hypersensitivity skin testing have been used for decades because of their sensitivity, reliability, and relative immediacy of results.
  • the widely-used Skin Prick (percutaneous) Test involves the manual application of as many as 40 standardized allergen extracts in a labeled array pattern on the patient's back or forearm, subsequently pricking the region with a needle to allow diffusion of allergens into the patient's epidermal tissue.
  • Intracutaneous is somewhat more invasive and labor intensive since it involves injecting small amounts of allergens into the patient's skin.
  • Intracutaneous testing is most often used to diagnose insect venom and drug allergies. Due to the nature of these processes, large areas of the subject's skin tend to be affected.
  • An allergy testing system has a microneedle array.
  • the allergy testing system also has at least one coated allergen.
  • the allergy testing system further has an activation system coupled to the microneedle array such that the at least one coated allergen is moved into contact with a subject as the microneedle array is moved from a resting position to a penetrating position.
  • Another allergy testing system is disclosed.
  • the allergy testing system has an attachment band having a test frame, wherein the test frame defines an opening in the attachment band.
  • the allergy testing system also has a package, for interfacing with the test frame.
  • the package has a microneedle array and coated allergens.
  • the allergy testing system also has an imaging system for interfacing with the test frame.
  • the allergy testing system further has an analyzer coupled to the imaging system.
  • a method for determining a degree of reaction to one or more allergens by a patient in a minimally invasive manner is disclosed.
  • One or more allergen coated microneedles is caused to penetrate into a skin of the patient.
  • One or more images of at least one of the penetrations into the skin are captured.
  • At least one of the captured images are analyzed to assess the degree of reaction to a specific allergen.
  • Allergic reactivity data is output for at least one of the allergens.
  • Another method for determining a degree of reaction to one or more allergens by a patient in a minimally invasive manner is disclosed.
  • One or more coated allergens on a sheet are wetted to dissolve the coated allergens.
  • One or more microneedles are caused to penetrate into a skin of the patient.
  • Each of the penetrations into the skin are exposed with dissolved coated allergens.
  • One or more images of each of the penetrations into the skin are captured. At least one of the captured images are analyzed to assess the degree of reaction to the specific allergen.
  • Allergic reactivity data is output for at least one of the allergens.
  • the claimed invention provides a system and method to minimize the invasiveness of allergy testing, degree and area of reaction, testing time, general discomfort, and risk of infection.
  • Another advantage of the claimed invention is that it enables a much smaller test area footprint when compared to prior testing devices.
  • the much smaller footprint also simplifies and expedites the allergy testing process for a medical staff.
  • the claimed invention uses dried allergens that are used only once, hence avoiding contamination and aging compared to the current method of liquid storage.
  • the allergen dispensing process may also be automated in some embodiments, allowing for automated and quantified allergy reactivity data readout, thereby reducing uncertainty and subjectivity.
  • a further advantage possible with automated embodiments is the ability to capture continuous or nearly continuous visual images of an allergy test site. This allows scientist and medical personnel a chance to study the time rate of change for certain allergic reactions, and better understand a patient's reaction and sensitivity. Overall, the minimally-invasive allergy testing system enables a relatively fast allergy test cycle time, lowers the cost of such testing, and significantly reduces the chance for errors.
  • FIGS. 1-2L schematically illustrate embodiments of an allergy testing system.
  • FIGS. 3 A & 3B to FIGS. 8 A & 8B schematically illustrate side views (A) and top views (B), respectively, of embodiments of microneedles for use in an allergy testing system.
  • FIG. 9 schematically illustrates a side view of a corrugated microneedle embodiment for use in an allergy testing system.
  • FIG. 1OA schematically illustrates an exploded perspective view of an embodiment of an allergy testing system.
  • FIG. 1OB schematically illustrates an assembled, cross-sectional view of the allergy testing system embodiment of FIG. 1OA.
  • FIG. 1 IA schematically illustrates an exploded perspective view of an embodiment of an allergy testing system.
  • FIG. 1 IB schematically illustrates an assembled, cross-sectional view of the allergy testing system embodiment of FIG. 1 IA.
  • FIGS. 12A - 12C schematically illustrate one possible method of applying allergens to a subject using an embodiment of an allergy testing system.
  • FIGS. 12Dl - 12D3 schematically illustrate different embodiments of gathering and analyzing allergy test data after the allergens have been applied by the allergy testing system in FIGS. 12A-12C.
  • FIG. 13 schematically illustrates an embodiment of an allergy testing system.
  • FIGS. 14A - 14B schematically illustrate a side view of an embodiment of an allergy testing system.
  • FIGS. 15 A - 15B schematically illustrate a top view of an embodiment of an allergy testing system.
  • FIG. 1 schematically illustrates an embodiment of a minimally invasive allergy testing system 20.
  • the minimally invasive allergy testing system 20 has a microneedle array 22 and at least one coated allergen 24.
  • the microneedle array 22 has at least one microneedle, and preferably a plurality of microneedles which may be spaced in a linear array, a two-dimensional array, or any other spacing desired.
  • the microneedles may have a height of about 50-1000 microns and a tip dimension ranging from submicron to about 80 microns in order to penetrate a subject's skin, although other embodiments may have other dimensions.
  • the microneedle 22 array may be manufactured out of a number of different substances, for example, silicon, glass, metal, quartz, or plastic. Due to its attractive micromachining properties, silicon may be etched using chemical and reactive ion etching processes to fabricate the microneedles, although other materials and manufacturing processes can be used.
  • the microneedle array 22 and the one or more coated allergens 24 may be aligned relative to each other by virtue of the coated allergens 24 being coated directly onto the microneedle array 22, or by virtue of the coated allergens 24 being coated on a another structure, such as a sheet, film, or label held in alignment relative to the microneedle array 22.
  • the minimally invasive allergy testing system 20 also has an activation system 26 which may be directly or indirectly coupled to the microneedle array 22. The activation system 26 causes a skin of a test subject to be pricked, while allowing the coated allergens 24 to dissolve within the subject's skin to initiate a controlled allergic reaction.
  • the coated allergens 24 may be dissolved prior to the pricking of the subject's skin by wetting the coated allergens 24 with a solvent.
  • the activation system 26 can be a mechanical plunger or other mechanical system, which is pressed by a medical professional, or even the test subject themselves.
  • the activation system 26 can be a spring- loaded release which allows a predictable force to be applied to the microneedle array 22 as it pricks the subject's skin.
  • Further embodiments of an allergy testing system 20 may have an activation system 26 which is an electro-mechanical system, such as a solenoid, motor, or a micromechanical actuator.
  • the microneedle array 22, the coated allergens 24, and/or the activation system 26 may be separate components of the allergy testing system 20.
  • the microneedle array 22 and the coated allergens 24 maybe removeably packaged from the activation system 26. This removeability allows for designs and embodiments with simple replacement of the microneedles and coated allergens which are typically only used once.
  • FIG. 2A illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 directly coupled to the activation system 26.
  • the microneedle array 22 may still be removeably coupled to the activation system 26 in some embodiments.
  • the microneedle array 22 is schematically illustrated in this and other embodiments as only having a single needle 28. It should be understood that any number of microneedles 28 may be present on the microneedle array 22, depending on size of the microneedle array 22 and the number of allergy test sites desired.
  • the activation system 26 and the microneedle array 22 are movcably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which one or more of the microneedles 28 may be moved.
  • the coated allergen 24 is coated directly onto the microneedle 28 of the microneedle array 22.
  • the coated allergen 24 may be coated onto the microneedle 28 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the microneedle 28.
  • the film forming agents may also be used to improve coatability and wetting during manufacturing.
  • a binder layer can be coated directly onto the microneedle 28 prior to coating with allergens. In the orientation of FIG.
  • the activation system 28 will engage downwards 34 to push the microneedles 28 of the microneedle array 22 into a subject's skin 36.
  • the activation system 26 may allow the coated microneedles 28 to penetrate the skin 36 for a period of time sufficient for the coated allergen 24 to dissolve in the fluids found within the subject's skin 36 and/or on the subject's skin 36, thereby allowing the allergen to enter the skin 36.
  • This time is variable and depends on the solubility of the allergen and any addenda. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • the allergy testing system embodied in FIG. 2A could also be pre-treated with a solvent, such as water, just prior to the administration of the allergy test to assist the coated allergens 24 in dissolving, or if it is simply desired to have the coated allergens 24 in dissolved form prior to penetrating the subject's skin.
  • a solvent such as water
  • access for wetting the coated allergens 24 may be provided through the orifices 32 in the package 30.
  • FIG. 2B schematically illustrates another embodiment of an allergy testing system 20 which is similar to the allergy testing system 20 of FIG. 2 A, with the addition of a sealing film 38 to cover the microneedle array 22 and the coated allergens 24.
  • the sealing film 38 may be employed over at least a portion of the package 30 to serve as a sterile layer protecting the sterile microneedles 28 and the coated allergens 24.
  • the sealing film 38 may be removed before use or left on the patient's skin 36. If left behind on the skin 36, the sealing film 38 may have a human readable code or a machine readable code 40, such as a bar code, or other identification marks 40. These identifying marks 40 can also be used for orientation in the analysis stage to be discussed later in this specification.
  • FIG. 2C schematically illustrates another embodiment of an allergy testing system 20 which is similar to the embodiment of FIG. 2B.
  • the embodiment of FIG. 2C has an access hole 42 defined by the package 30 which may be used to provide access for a solvent to be applied to the coated allergen 24 prior to administration of the allergy test.
  • a sealing flap 44 may be provided in some embodiments to cover the access hole 42 to allow a solvent to be agitated within the orifice 32 without leaking prior to administration of an allergy test or removal of the sealing film 38.
  • FIG. 2D schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26, The activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the coated allergen 24 is coated directly onto the microneedle array 22, but not in the area of the microneedle 28.
  • the coated allergen 24 may be coated onto the microneedle array 22 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the microneedle array 22.
  • a binder layer can be coated directly onto the microneedle array 22 prior to coating with allergens.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via the orifice 32. These wetted allergens may then coat the microneedle 28. Once the coated allergens 24 have been wetted, the activation system 26 may be engaged downwards 34 to push the microneedles 28 of the microneedle array 22 into a subject's skin 36. The activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times. [00039] FIG. 2E schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 may be configured to have the microneedle array 22 coupled to the activation system 26, however, for simplicity, the activation system is illustrated in this embodiment separate from the microneedle array 22.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the coated allergen 24 is coated directly onto the microneedle array 22, but not on the side of the microneedle array 22 having the microneedle 28. Instead, in this embodiment, the coated allergen 24 is coupled to a second side of the microneedle array 22.
  • the coated allergen 24 may be coated onto the microneedle array 22 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the microneedle array 22.
  • a binder layer can be coated directly onto the microneedle array 22 prior to coating with allergens.
  • the package 30 defines a channel 46 which fluidically couples the microneedle 28 side of the microneedle array 22 to the side of the microneedle array 22 with the coated allergen 24.
  • the channel 46 may be provided by the microneedle array 22 or a combination of the microneedle array 22 and the package 30.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via the orifice 32 and the channel 46.
  • FIG. 2F schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 may be configured to have the microneedle array 22 coupled to the activation system 26, however, for simplicity, the activation system 26 is illustrated in this embodiment separate from the microneedle array 22.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved, hi this embodiment, the coated allergen 24 is coated directly onto the microneedle array 22, but not on the side of the microneedle array 22 having the microneedle 28. Instead, in this embodiment, the coated allergen 24 is coupled to a second side of the microneedle array 22.
  • the coated allergen 24 may be coated onto the microneedle array 22 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda.
  • the microneedle 28 defines a channel 48 which fluidically couples the microneedle 28 side of the microneedle array 22 to the side of the microneedle array with the coated allergen 24.
  • the coated allergens 24 may be wetted with a solvent via an access hole 42.
  • the access hole 42 may be provided with a plug 44 for removeably sealing the access hole 42.
  • FIG. 2G schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 may be configured to have the microneedle array 22 coupled to the activation system 26, however, for simplicity, the activation system 26 is illustrated in this embodiment separate from the microneedle array 22.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the coated allergen 24 is coated directly onto the microneedle array 22, but not on the side of the microneedle array 22 having the microneedle 28. Instead, in this embodiment, the coated allergen 24 is coupled to a second side of the microneedle array 22.
  • the coated allergen 24 may be coated onto the microneedle array 22 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the microneedle array 22.
  • a binder layer can be coated directly onto the microneedle array 22 prior to coating with allergens.
  • the microneedle 28 defines a channel 48 which fluidically couples the microneedle 28 side of the microneedle array 22 to the side of the microneedle array with the coated allergen 24.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via the orifice 32 and the channel 48. After wetting, when the activation system 26 is engaged downwards 34 to push the microneedles 28 of the microneedle array 22 towards a subject's skin 36, the motion of the activation system 26 against the microneedle array 22 may squeeze the wetted allergens out the channel 48, through the microneedle 28, and into the skin 36 as the microneedle 28 penetrates the skin 36 for a desired period of time.
  • FIG. 2H schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the allergy testing system 20 also has a sheet 50 coupled to the package 30. One side of the sheet 50 is disposed towards the microneedle array 22 and the other side of the sheet 50 is disposed away from the microneedle array 22.
  • the coated allergen 24 is coated directly onto the side of the sheet 50 facing away from the microneedle array 22.
  • the coated allergen 24 may be coated onto the sheet 50 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the sheet 50. Sheet 50 may even be selected for its properties in allowing the allergens to coat properly thereon without the need for a binder.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via the orifice 32.
  • the activation system 26 may then be engaged downwards 34 to push the microneedles 28 of the microneedle array 22 through the sheet 50, supporting the now dissolved allergens 24, and into a subject's skin 36.
  • the activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • FlG. 21 schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the allergy testing system 20 also has a sealing film 38 coupled to the package 30 and covering at least a portion of the orifice 32.
  • One side of the sealing film 38 is disposed towards the microneedle array 22 and the other side of the sealing film 38 is disposed away from the microneedle array 22.
  • the coated allergen 24 is coated directly onto the side of the sealing film 38 facing away from the microneedle array 22.
  • the coated allergen 24 may be coated onto the sealing film 38 as a pure extract, or can be dissolved into a solution containing film fo ⁇ ning agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the sealing film 38. Sealing film 38 may even be selected for its properties in allowing the allergens to coat properly thereon without the need for a binder.
  • film fo ⁇ ning agents such as glycerol, biocompatible water soluble polymer, or other addenda.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent. The sealing film and wetted allergens may then be placed against the subject's skin 36, and the activation system 26 may then be engaged downwards 34 to push the microneedles 28 of the microneedle array 22 through the sealing film 38, supporting the now dissolved allergens 24, and into a subject's skin 36. The activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • FIG. 2J schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the allergy testing system 20 also has a sheet 50 coupled to the package 30. One side of the sheet 50 is disposed towards the microneedle array 22 and the other side of the sheet 50 is disposed away from the microneedle array 22.
  • the coated allergen 24 is coated directly onto the side of the sheet 50 facing towards the microneedle array 22.
  • the coated allergen 24 may be coated onto the sheet 50 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the sheet 50. Sheet 50 may even be selected for its properties in allowing the allergens to coat properly thereon without the need for a binder.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via an access hole 42 defined by the package 30. A plug 44 may be provided to removeably seal the access hole 42.
  • the activation system 26 may then be engaged downwards 34 to push the microneedles 28 of the microneedle array 22 through the dissolved allergens 24, supported by the sheet 50, and into a subject's skin 36.
  • the activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • FIG. 2K schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the package 30 defines at least one orifice 32 within which the microneedle 28 may be moved.
  • the allergy testing system 20 also has a sealing film 38 coupled to the package 30 and covering at least a portion of the orifice 32.
  • One side of the sealing film 38 is disposed towards the microneedle array 22 and the other side of the sealing film 38 is disposed away from the microneedle array 22.
  • the coated allergen 24 is coated directly onto the side of the sealing film 38 facing towards the microneedle array 22.
  • the coated allergen 24 may be coated onto the sealing film 38 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the sealing film 38. Sealing film 38 may even be selected for its properties in allowing the allergens to coat properly thereon without the need for a binder.
  • film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via an access hole 42 defined by the package 30. A plug 44 may also be provided to removeably seal the access hole 42.
  • the sealing film may then be placed against the subject's skin 36, and the activation system 26 may then be engaged downwards 34 to push the microneedles 28 of the microneedle array 22 through the dissolved allergens 24 supported by the sealing film 38, and into a subject's skin 36.
  • the activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • FIG. 2L schematically illustrates another embodiment of an allergy testing system 20.
  • This allergy testing system 20 has the microneedle array 22 coupled to the activation system 26.
  • the activation system 26 and the microneedle array 22 are moveably supported by a package 30.
  • the allergy testing system 20 also has a sheet 52 coupled to the microneedle array 22.
  • One side of the sheet 52 is disposed towards the microneedle array 22 and the other side of the sheet 52 is disposed away from the microneedle array 22.
  • the coated allergen 24 is coated directly onto the side of the sheet 52 facing away from the microneedle array 22.
  • the coated allergen 24 may be coated onto the sheet 52 as a pure extract, or can be dissolved into a solution containing film forming agents such as glycerol, biocompatible water soluble polymer, or other addenda. These film forming agents operate as binders which assist the coated allergen 24 in adhering to the sheet 52. Sheet 52 may even be selected for its properties in allowing the allergens to coat properly thereon without the need for a binder.
  • the coated allergens 24 Prior to activating the allergy testing system 20, the coated allergens 24 may be wetted with a solvent via the orifice 32. The activation system 26 may then be engaged downwards 34 to push the microneedles 28 and the sheet 50, supporting the now dissolved allergens 24, and into contact with a subject's skin 36.
  • the microneedle 28 When the sheet 52 reaches the skin 36, the microneedle 28 will be able to exert pressure on the sheet 52, piercing it, and penetrating the skin along with the dissolved allergens 24 which were on the sheet.
  • the activation system 26 may allow the microneedles 28 with allergens 24 to penetrate the skin 36 for a desired period of time. Useful times for some embodiments may be in the range of 0.3-5.0 seconds, however other embodiments may require shorter or longer times.
  • FIGS. 3 A and 3B schematically illustrate an embodiment of a microneedle 54 with a substantially square or rectangular cross-section in a side view and a corresponding top view, respectively.
  • FIGS. 4A and 4B schematically illustrate an embodiment of a microneedle 56 with a substantially circular cross-section in a side view and a corresponding top view, respectively.
  • the microneedle embodiment shown in FIG. 4A illustrates another variation possible with microneedle design.
  • the microneedle 56 has a wedged top. Although other embodiments are not shown wedged, they could be modified in further embodiments to have a wedge-shaped top.
  • FIGS. 5 A and 5B schematically illustrate an embodiment of a microneedle 58 with a substantially triangular cross-section in a side view and a corresponding top view, respectively.
  • FIGS. 6 A and 6B schematically illustrate an embodiment of a microneedle 60 with a substantially square or rectangular cross-section in a side view and a corresponding top view, respectively.
  • This microneedle is a hollow microneedle, having a channel formed within the needle for the passage of allergens.
  • FIGS. 7A and 7B schematically illustrate an embodiment of a microneedle 62 with a substantially square or rectangular cross-section in a side view and a corresponding top view, respectively.
  • This microneedle is a grooved microneedle, having a channel formed on the side of the needle for the passage of allergens.
  • FIGS. 8A and 8B schematically illustrate an embodiment of a microneedle 64 with a changing cross-sectional area that tapers to a point.
  • Any of the features of the microneedles in the embodiments of FIGS. 3A- 8B may be combined with one another, and cross-sectional shapes may be varied.
  • a microneedle could be both hollowed and grooved at the same time.
  • the microneedles may have a height of about 50-1000 microns and a tip dimension from submicron to about 80 microns in order to penetrate a subject's skin, although other embodiments may have other dimensions.
  • the microneedle array may be manufactured out of a number of different substances, for example, silicon, glass, metal, or plastic. Due to its attractive micromachining properties, silicon may be anisotropically etched using chemical and reactive ion etching processes to fabricate the microneedles, although other materials and manufacturing processes can be used.
  • FIG. 9 A further embodiment of a microneedle 66 is schematically illustrated in FIG. 9.
  • the microneedle is corrugated around a generally pointed microneedle structure. Corrugated needle designs like this one may facilitate the entry and exit of the microneedle from the test subject 36 with a reduced amount of force.
  • the corrugations may also provide channels for the allergens to enter a puncture site.
  • the corugations can also provide higher surface area to enahance the amount of material diffusing.
  • FIGS. 1OA and 1OB another embodiment of a minimally invasive allergy testing system 68 is schematically illustrated in an exploded perspective view and an assembled side cross-sectional view, respectively.
  • the allergy testing system includes a microneedle substrate 70 that supports an array of microneedles 72 with integral mesas 74.
  • the mesas 74 are not absolutely necessary, but in some embodiments, they can provide stability for the microneedles 72 as the microneedles are engaged. (This will be explained in more detail later.)
  • a linear array of microneedles 72 having mesas 74 are illustrated in this embodiment, but other embodiments may have other numbers and types of components in other shapes and configurations.
  • the substrate 70, microneedles 72, and mesas 74 may be manufactured from a number of different materials, such as silicon, glass, metal, or plastic.
  • the microsystem allergy testing device 68 also includes a package assembly 76 which houses the substrate 70, microneedles 72, and mesas 74 such that the top surface of substrate 70 rests against a compressible stop 78 along an inner surface of the package 76.
  • the compressible stop 78 may be permanently compressible, or may be an energy storage device such as a spring.
  • the microneedles 72 are mounted for movement within the package 76 from a position where the upper tips of the microneedles 72 lie within orifices 80, such that they do not protrude significantly outside of the package assembly 76, to a position protruding outside of the package assembly 76.
  • This embodiment also has a thin sealing film 82 employed over a surface of the package assembly 76.
  • a set of coated allergens 84 associated with each microneedle 72 is coated on the sealing film 82.
  • the coated allergens 84 may be wet with a solvent so that the coated allergens 84 may be dissolved.
  • the sealing film 82 may have hydrophobic ai ⁇ eas between coated allergens 84 to help prevent intermixing of the dissolved allergens. Such hydrophobic areas may also allow the applied water to selectively wet the allergens 84.
  • the sealing film 82 may also have human readable, barcode, or other identifying marks 86. Such identifying marks have been discussed above with regard to previous embodiments.
  • This embodiment of an allergy testing system 68 also has a plunger 88.
  • the plunger 88 may be activated by an activation system (not shown), such as manual pressure, mechanical systems, electromechanical systems, piezoelectric, or a micrornechanical actuator.
  • Pressure applied to the plunger 88 causes substrate 70 to compress resting stop 78, allowing the microneedles 72 to protrude out of the package assembly 76, pierce through the sealing film 82 and the coated allergens 84 towards the patient's skin (not shown in this figure, but in this embodiment, the test subject would be above the allergy testing system 68 as oriented.)
  • the plunger 88 is depressed far enough, the microneedles 72 pierce the patient's skin while mesas 74 fit into orifices 80 in package 76 to help increase travel and positional stability of the microneedles 72.
  • FIGS. 1 IA and 1 IB another embodiment of a minimally invasive allergy testing system 90 is schematically illustrated in an exploded perspective view and an assembled side cross-sectional view, respectively.
  • the allergy testing system 90 includes a microneedle substrate 70 that supports an array of microneedles 72 with integral mesas 74.
  • the mesas 74 are not absolutely necessary, but in some embodiments, they can provide stability for the microneedles 72 as the microneedles are engaged.
  • a linear array of microneedles having mesas are illustrated in this embodiment, but other embodiments may have other numbers and types of components in other shapes and configurations.
  • the substrate 70, microneedles 72, and mesas 74 may be manufactured from a number of different materials, such as silicon, glass, metal, or plastic.
  • the microneedles 72 are coated with allergens 92, similar to the coated microneedles of FIG. 2A.
  • the microsystem allergy testing device 90 of FIGS. HA and HB also includes a package assembly 76 which houses the substrate 70, microneedles 72, and mesas 74 such that the top surface of substrate 70 rests against a compressible stop 78 along an inner surface of the package 76.
  • the compressible stop 78 may be permanently compressible, or may be an energy storage device such as a spring.
  • the microneedles 72 are mounted for movement within the package 76 from a position where the upper tips of the microneedles 72 lie within orifices 80, such that they do not protrude significantly outside of the package assembly 76, to a position protruding outside of the package assembly 76.
  • This embodiment of an allergy testing system 90 also has a plunger 88.
  • the plunger 88 may be activated by an activation system (not shown), such as manual pressure, mechanical systems, electromechanical systems, piezoelectric, or a. micromechanical actuator.
  • FIGS. 1-10 Pressure applied to the plunger 88 causes substrate 70 to compress resting stop 78, allowing the microneedles 72 to protrude out of the package assembly 76 towards the patient's skin (not shown in this figure, but in this embodiment, the test subject would be above the allergy testing system 90 as oriented.)
  • the plunger 88 When the plunger 88 is depressed far enough, the allergen coated microneedles 72 pierce the patient's skin while mesas 74 fit into orifices 80 in package 76 to help increase travel and positional stability of the microneedles 72.
  • the microneedles 72 may then remain in the skin long enough for the coated allergens 92 to dissolve into the fluids found in the skin, for example, interstitial fluid.
  • FIG. 12A schematically illustrate one possible method of applying allergens to a subject using an embodiment of an allergy testing system.
  • the minimally invasive allergy testing system 90 is placed in contact with a subject's skin 36. Since this embodiment of an allergy testing system 90 does not have a sealing film, the package assembly 76 is the portion of the test system initially in contact with the skin 36. In other systems, the portion initially in contact with the skin 36 might be a sealing film.
  • the microneedle array is in a resting position.
  • FIG. 12B the plunger 88 is activated, in the orientation of FIG. 12B, in a downward direction, causing the substrate 70 to compress the compressible stop 78.
  • the microneedles 72 with coated allergens 92 puncture the skin 36.
  • the microneedle array is in a penetrating position. After a time sufficient for the allergens 92 to dissolve into the patient's skin 36, the force on the plunger 88 is released, causing it to return to the resting position shown in FIG. 12C. After this procedure, the allergens 92 originally carried by the microneedles 72 are able to diffuse into the subject through the pricked regions 94, thereby potentially initiating allergic reactions.
  • microneedles of differing lengths on the same substrate 70 may be used.
  • a benefit of providing different length microneedles may be to allow different allergens to reach a targeted skin depth, or to test the same allergen at different depths for studied comparisons.
  • FIGS. 12Dl - 12D3 schematically illustrate different embodiments of gathering and analyzing allergy test data after the allergens have been applied by the allergy testing system in FIGS. 12A-12C.
  • FIG. 12Dl schematically illustrates a test subject's skin 36 which has been pricked and injected with allergens 92 by the microneedles 72 of a minimally invasive allergy testing system 90.
  • a schematic human eye 96 is looking for a reaction 98 to a particular allergen 92.
  • a template may be included that matches the applied allergens so as to help identify the corresponding reactions.
  • FIG. 12D2 schematically illustrates an embodiment of an allergy analysis system 100 which can optionally be used in place of or in conjunction with manual evaluation methods.
  • the allergy analysis system 100 includes an imaging module 102 with imaging optics 104.
  • the imaging optics 104 focuses images of the tested skin area on an image sensor 106.
  • the image sensor 106 is coupled to an image analyzer or processor 108.
  • the image analyzer 108 can analyze the captured images for color, shape, dimension, and location in the test field.
  • the analyzer 108 determines reactivity data for each allergen.
  • the reactivity data, as well as the captured images may be stored, displayed, transmitted, and/or printed by the- analyzer 108.
  • the analyzer may output this data to another processor for storage, display, further analysis, transmission, and/or printing.
  • the analyzer 108 is directly coupled to the allergy analysis system 100.
  • the analyzer 108 may be remotely coupled to the analysis system 100 via a wireless or cabled link.
  • the image analyzer 108 may comprise a central processing unit (CPU) or processor and a memory which are coupled together by a bus or other link, although other numbers and types of components in other configurations and other types of systems, such as an application specific integrated circuit (ASIC) could be used.
  • the processor may execute a program of stored instructions for one or more aspects of the' claimed invention, including the method for determining a degree of reaction to one or more allergens as described and illustrated herein.
  • the memory stores these programmed instructions for execution by the processor.
  • a variety of different types of memory storage devices such as random access memory (RAM) or a read only memory (ROM) in the system or a floppy disk, hard disk, CD ROM, or other computer readable medium which is read from and/or written to by a magnetic, optical, or other reading and/or writing system that is coupled to the processor, can be used for the memory to store these programmed instructions.
  • the image analyzer 108 can be in situ (as illustrated) or remote (for example, separate electronics or a separate computing device) linked by a wired or wireless connection.
  • the skin puncture site 110 shows a positive allergy reaction 98, while skin puncture sites 112, 114 show negative allergy reactions.
  • the imaging module 102 should be placed in alignment with the original allergy testing device 90 (from FIGS. 12A - 12C) such that the imaging optics 104 creates images of test sites 110, 112, and 114. These test sites 110, 112, 114 are associated with each allergen in correlated locations on image sensor 106. Tmage patterns associated with each allergen, as imaged by sensor 106, are captured and transmitted to image analyzer 108 for analysis as described above in order to identify color, shape, dimension, allergic reaction, and/or a time rate of change of the allergic response.
  • an allergy testing system which have an allergy imaging analysis system 100, it maybe important to determine topographic information when assessing reactivity to an allergen.
  • an extra set of imaging optics and an extra image sensor may be displaced laterally from the other optical system to obtain stereoscopic, parallax information about a given test location. Parallax information may in turn be used to calculate topographic profiles of test regions.
  • FIG. 12D3 schematically illustrates an embodiment of a minimally invasive allergy testing system 116 with an. integrated imaging and analysis module 102.
  • the microneedle array 118 and plunger 120 operate in similar fashion to the corresponding elements in FIG. 12A, except as described herein.
  • the array of microneedles 118 and plunger 120 are made of glass or some other transparent material, such as transparent hard plastic, such that imaging module 102 may image the tested regions with the needles in-situ, or even slightly or completely retracted.
  • the width of the microneedles 122 relative to their spacing should be fine enough to allow enough imaging area for an adequate diagnosis of the allergic reaction.
  • FIG. 13 schematically illustrates a further embodiment of a minimally invasive allergy testing system 124.
  • the allergy testing system 124 is coupled to a band 126 which may be wrapped around a portion of a person's body.
  • the part of the body illustrated is an arm 128.
  • attachment band 126 could be compatible with or modified to attach to other portions of the body.
  • Attachment band 126 need not circle completely around and back to itself, although preferred embodiments may have Velcro ® attachments which wrap around the body and then connect to themselves.
  • the purpose of the attachment band 126 is to hold a test frame 130 in substantially the same position during a minimally invasive allergy test.
  • the test frame 130 defines an opening in the band 126 through which the skin may be accessed.
  • the test frame 130 also has a first alignment coupling, such as a hinge 132 onto which a package 134 containing a microneedle array having coated allergens may be placed for aligned engagement with the skin in the test frame 130.
  • the test frame 130 has a second alignment coupling, such as a hinge 136 onto which an allergy imaging system 138 maybe placed for aligned engagement with the skin in the test frame 130.
  • the allergen and microneedle package 134 will be engaged with the test frame at different times from the imaging system 138.
  • both the allergen and microneedle package 134 and the imaging system 138 may be engaged at the same time.
  • the alignment coupling docs not have to be a hinged connection. It may, instead, be a temporary guide for the manual placement of an otherwise loose portion of the testing system, such as the allergen package 134, or the imaging system 138.
  • the analyzer 140 is illustrated as being remotely coupled to the imaging system 138. This remote link may be a physical wire or a radio frequency (RF) or optical wireless link.
  • RF radio frequency
  • FIG. 14A schematically illustrates a side view of an imaging system 142 which, holds a replaceable microneedle allergen package 144.
  • the microneedle package 144 may be held in position by guides on the imaging system 142.
  • FIG. 14B schematically illustrates the microneedle allergen package 144 being removed from the imaging system 142 in a substantially linear 146 direction.
  • a microneedle allergen package 144 could be installed by reversing the action illustrated in FIG. 14B. After inserting an allergen package 144, the microneedles may be engaged by the activation system as described in previous embodiments.
  • FIG. 15A schematically illustrates a top view of another embodiment of an imaging system 148 which holds a replaceable microneedle allergen package 150.
  • the microneedle package 150 is held in place by a pivot point 152 and may also be held in position by guides on the imaging system 148.
  • FIG. 15B schematically illustrates the microneedle allergen package 150 being removed from the imaging system 148 in a substantially arcuate 154 direction.
  • a microneedle allergen package 150 could be installed by reversing the action illustrated in FIG. 15B.
  • the microneedles may be engaged by the activation system as described in previous embodiments. Then, once the microneedles are allowed to retract, the allergen package 150 can be removed from the optical path of the imaging sensor within the imaging system 148 as illustrated in FIG. 15B.
  • non-transparent or non-optical materials can be used for the microneedle array, such as silicon, metal, opaque plastic, and others. In some cases, it may even be desirable to remove transparent materials away from the optical path in order to reduce requirements for optical flatness, transparency, and cost.
  • sheets, thin-films, films, and labels have been described as being used on some embodiments of allergy testing systems and/or on the replaceable allergy testing cartridges, depending on where they were located.
  • AU are considered to be equivalents of each other, and for the purposes of the claims, the terms are interchangeable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un système de test d'allergie comprenant un réseau de micro-aiguilles. Ce système de test d'allergie comprend également au moins un enrobage d'allergènes. Le système de test d'allergie est également équipé d'un système d'activation couplé au réseau de micro-aiguilles de telle sorte que l'enrobage d'allergènes soit déplacé afin d'entrer en contact avec un sujet pendant que le réseau de micro-aiguille est déplacé depuis une position de repos vers une position de pénétration. L'invention concerne également un procédé permettant de déterminer un degré de réaction d'un patient à un ou à plusieurs allergènes de manière peu invasive. Selon le procédé susmentionné, une ou plusieurs micro-aiguilles recouvertes d'allergènes sont introduites dans la peau du patient. Une ou plusieurs images de/des pénétrations des micro-aiguilles dans la peau sont capturées. Au moins l'une des images capturées est analysée afin d'évaluer le degré de réaction à un allergène spécifique. Des données de réactivité allergique sont produites pour l'un au moins des allergènes.
PCT/US2007/061604 2006-07-11 2007-02-05 Système de test d'allergie peu invasif pourvu d'enrobages d'allergènes Ceased WO2008008558A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/373,385 US20100100005A1 (en) 2006-07-11 2007-02-05 Minimally invasive allergy testing system with coated allergens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2006/026774 WO2007008824A2 (fr) 2005-07-11 2006-07-11 Systeme de test d'allergie avec effraction minimale
PCT/US2006/026734 WO2007008800A2 (fr) 2005-07-11 2006-07-11 Cartouche remplacable destinee a systeme de test d'allergie
USPCT/US2006/26734 2006-07-11
USPCT/US2006/26774 2006-07-11

Publications (1)

Publication Number Publication Date
WO2008008558A1 true WO2008008558A1 (fr) 2008-01-17

Family

ID=38923547

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/061604 Ceased WO2008008558A1 (fr) 2006-07-11 2007-02-05 Système de test d'allergie peu invasif pourvu d'enrobages d'allergènes
PCT/US2007/061601 Ceased WO2008008557A1 (fr) 2006-07-11 2007-02-05 Cartouche pour tests d'allergie comprenant un enrobage d'allergènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/061601 Ceased WO2008008557A1 (fr) 2006-07-11 2007-02-05 Cartouche pour tests d'allergie comprenant un enrobage d'allergènes

Country Status (1)

Country Link
WO (2) WO2008008558A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319742A1 (en) * 2009-09-08 2011-12-29 SensiVida Medical Technologies, Inc. Spatial imaging methods for biomedical monitoring and systems thereof
FR3064904A1 (fr) * 2017-04-10 2018-10-12 Universite De Rennes 1 Dispositif de test d'allergies.
US11000042B2 (en) 2007-07-11 2021-05-11 Clene Nanomedicine, Inc. Continuous methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) resulting therefrom

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227286B1 (fr) * 2007-11-28 2017-04-19 Janisys Limited Dispositif de distribution pour l'administration d'une substance active à un sujet
CA2734778C (fr) * 2008-08-21 2017-06-06 Third Rock Ventures Dispositif d'evaluation de medicament et de traitement local
US9168364B2 (en) 2008-11-04 2015-10-27 Janisys Limited Transfer device for transferring a substance between the device and a subject
WO2013102034A1 (fr) 2011-12-30 2013-07-04 Kibur Medical, Inc. Dispositifs implantables et procédés pour l'évaluation d'un agent actif
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
KR102604753B1 (ko) * 2018-05-18 2023-11-22 포항공과대학교 산학협력단 경피 투과형 약물 전달 패치의 제조 방법
DE102020109157A1 (de) * 2020-04-02 2021-10-07 Lts Lohmann Therapie-Systeme Ag Trägerelement für Mikronadeln sowie Mikronadelarray-Einrichtung
EP4404824A1 (fr) * 2021-09-22 2024-07-31 Danmarks Tekniske Universitet Test d'allergie transdermique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169411A1 (en) * 2001-05-11 2002-11-14 The Procter & Gamble Co. Portable interstitial fluid monitoring system
US20050137536A1 (en) * 2001-09-28 2005-06-23 Gonnelli Robert R. Microneedle with membrane
US20050137531A1 (en) * 1999-11-23 2005-06-23 Prausnitz Mark R. Devices and methods for enhanced microneedle penetration of biological barriers
US20050228340A1 (en) * 2004-03-24 2005-10-13 Cleary Gary W Transdermal delivery device
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
US20060047242A1 (en) * 2004-08-25 2006-03-02 Becton, Dickinson And Company Method and device for the delivery of a substance including a covering
US20060094985A1 (en) * 2002-02-08 2006-05-04 Rosedale Medical Autonomous, ambulatory analyte monitor or drug delivery device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5335670A (en) * 1986-04-18 1994-08-09 Henry Fishman Allergy testing method and apparatus
US5605160A (en) * 1986-04-18 1997-02-25 Fishman; Henry Allergy testing apparatus with variably spaced test testing sites
DE3887145T2 (de) * 1987-05-29 1994-04-28 North Sydney Area Health Serv Medizinische Testvorrichtung.
US5139029A (en) * 1990-04-06 1992-08-18 Henry Fishman Allergy testing apparatus and method
US5104620A (en) * 1990-07-30 1992-04-14 Wiley Fred R Disposable allergy skin testing kit
US5671753A (en) * 1995-06-27 1997-09-30 Pitesky; Isadore Disposable multiple allergen testing apparatus
US6095988A (en) * 1998-09-04 2000-08-01 Greer Laboratories, Inc. Autoloader and skin testing system

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137531A1 (en) * 1999-11-23 2005-06-23 Prausnitz Mark R. Devices and methods for enhanced microneedle penetration of biological barriers
US20020169411A1 (en) * 2001-05-11 2002-11-14 The Procter & Gamble Co. Portable interstitial fluid monitoring system
US20050137536A1 (en) * 2001-09-28 2005-06-23 Gonnelli Robert R. Microneedle with membrane
US20060094985A1 (en) * 2002-02-08 2006-05-04 Rosedale Medical Autonomous, ambulatory analyte monitor or drug delivery device
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
US20050228340A1 (en) * 2004-03-24 2005-10-13 Cleary Gary W Transdermal delivery device
US20060047242A1 (en) * 2004-08-25 2006-03-02 Becton, Dickinson And Company Method and device for the delivery of a substance including a covering

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000042B2 (en) 2007-07-11 2021-05-11 Clene Nanomedicine, Inc. Continuous methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) resulting therefrom
US20110319742A1 (en) * 2009-09-08 2011-12-29 SensiVida Medical Technologies, Inc. Spatial imaging methods for biomedical monitoring and systems thereof
FR3064904A1 (fr) * 2017-04-10 2018-10-12 Universite De Rennes 1 Dispositif de test d'allergies.
WO2018189452A1 (fr) * 2017-04-10 2018-10-18 Universite De Rennes 1 Dispositif de test d'allergies

Also Published As

Publication number Publication date
WO2008008557A1 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
US20100100005A1 (en) Minimally invasive allergy testing system with coated allergens
WO2008008558A1 (fr) Système de test d'allergie peu invasif pourvu d'enrobages d'allergènes
US7942827B2 (en) Minimally invasive allergy testing system
JP4726948B2 (ja) 格納式ランセットを持った統合化切開テストストリップ
CN100591273C (zh) 用于分析体液的系统
US20060211933A1 (en) Monitoring method and/or apparatus
JP4959545B2 (ja) 体液サンプリング装置および体液分析を行うシステム
Smart et al. The use of silicon microfabrication technology in painless blood glucose monitoring
EP2493537B1 (fr) Systèmes et procédés de traitement, désinfection et/ou protection de la peau ou des dispositifs appliqués sur la peau
US8628724B2 (en) Integrated needle and test strip with aspiration apparatus and method of use
JP2002078698A (ja) マイクロニードルパッチ、それを用いた血液監視システム及び血液中の化学物質の濃度を測定する方法
US20150057510A1 (en) Patient-enacted sampling technique
US20050234368A1 (en) Integrated spot monitoring device with fluid sensor
WO2016164208A1 (fr) Extraction in vivo de fluide interstitiel à l'aide de micro-aiguilles creuses
KR20060048600A (ko) 통합형 바이오센서의 제조 방법
CN101374459A (zh) 集成的分析测试元件
WO2011053787A2 (fr) Systèmes et procédés pour application à la peau et commande de l'activation, de la délivrance et/ou de la perception de ceux-ci
WO2013186628A1 (fr) Dispositif transdermique de détection fluorométrique d'un analyte dans un liquide biologique et appareil d'analyse associé audit dispositif transdermique
US20230077165A1 (en) Interstitial Fluid Sampling Device
KR20170110279A (ko) 흡착부를 구비한 채혈 방법 및 장치
US20160113561A1 (en) Apparatus and method for detecting and/or monitoring one or more compounds in blood
WO2017100480A1 (fr) Appareil et procédé de détection et/ou de surveillance d'un ou de plusieurs composés dans le sang
US11931537B2 (en) Practice-loadable minimally invasive allergy test system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07710452

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07710452

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12373385

Country of ref document: US